Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. (Q52846107)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 March 2011

Language	Label	Description	Also known as
English	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.	scientific article published on 2 March 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Fátima Cardoso

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Philippe Bougnoux

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Joyce O'Shaughnessy

2

object named as

Joyce O'Shaughnessy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

20

object named as

Chris Twelves

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

4

object named as

Joanne L Blum

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Nicole L Meneses

18

object named as

Nicole Meneses

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

David Loesch

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Katarina Petrakova

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Philippe Chollet

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Alexey Manikas

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Veronique Diéras

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Thierry Delozier

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Vladimir Vladimirov

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Han Koh

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Corina E Dutcus

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Seth Seegobin

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Denis Mir

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Jantien Wanders

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

language of work or name

0 references

publication date

2 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

377

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

9769

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

914-923

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Overview of resistance to systemic therapy in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960070-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(11)60070-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376385%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52846107&oldid=1858375073"